ADNI
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.